Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2002

Gillies Stephen D, Lo Kin-Ming, Burger Christa, Lan Yan, Dahl Thomas, Wong Wai-Keung

Abstract excerpt

PURPOSE: Previous studies showed that reducing the interaction of antibody-interleukin 2 immunocytokines with Fc receptors improved their circulating half-life in mice and increased their antitumor activity. We sought to modify sequences that would increase half-life but retain the ability to activate Fc receptor-mediated effector functions. EXPERIMENTAL DESIGN: Modified immunocytokines were assessed in vitro for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cathepsin L
Share to Cathepsins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cysteine Endopeptidases

Share to Half-Life

Share to Immunoconjugates

Share to Immunoglobulin Fc Fragments

Share to Interleukin-2

Share to Transplantation, Heterologous

Source

Identifiers

PMID: 11801561

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis.PMID 11801561Read ↗

Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting Clq and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse.Semantic proximity Read ↗

A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.Semantic proximity Read ↗

Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.Semantic proximity Read ↗

A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics.Semantic proximity Read ↗

Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.Semantic proximity Read ↗

The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.Semantic proximity Read ↗

Regulating Cytokine Function Enhances Safety and Activity of Genetic Cancer TherapiesSemantic proximity Read ↗

Intracellular expression of single chain antibodies reverts ErbB-2 transformation.Semantic proximity Read ↗

Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.Semantic proximity Read ↗

Engineered human IgG antibodies with longer serum half-lives in primates.Semantic proximity Read ↗

Optimizing the binding affinity of a carrier protein: a case study on the interaction between soluble ifnar2 and interferon beta.Semantic proximity Read ↗

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.